Mubadala Capital, QIA Led USD50 Million Series B Funding for Lambic Therapeutics

– Iambic Therapeutics, a US-based clinical-stage biotechnology company, has secured an additional $50 million in Series B extension funding, led by Mubadala Capital. – This extension builds on a $100 million Series B round completed...